Pasar al contenido principal

Supporting the production of quality livestock vaccines for enterotoxemia, Pasteurella and Rift Valley fever in Kenya


Kenya has an estimated 18.2 million cattle, 16.3 million sheep, and 24.6 million goats. The majority of these animals are held by smallholder farmers who depend on livestock for their livelihoods. However, approximately 25% of these animals succumb to preventable diseases such as enterotoxemia, Pasteurella, and Rift Valley fever. This causes significant economic and social hardship to poor farmers, in addition to having a negative impact on the national economy. Rift Valley fever is of particular concern because it is transmissible between livestock and humans.

Transferring capacity for increased availability

MCI Santé animale in Morocco will transfer a supply of vaccine bulk antigens to the Kenya Veterinary Vaccines Production Institute (KEVEVAPI). By establishing product formulation and quality control systems in a Kenyan institution, Kenya will acquire the capacity to produce and register three new vaccines of international quality standards that will be more readily available to smallholder farmers.

Expected results

The expected outcome of this project is that KEVEVAPI will acquire the technology and capacity to process bulk antigens into high-quality vaccines. This project is also piloting this model of bulk antigen processing which, if successful, could be used for other vaccine types to ensure improved availability of high quality vaccines to livestock smallholders across East Africa.

Lead institutions

This project is led by MCI Santé animale of Morocco and the Kenya Veterinary Vaccines Production Institute.

  • Duration: 18 months
  • Budget: CA$213,000